Volume : 11, Issue : 12, December – 2024
Title:
THE ROLE OF TRANEXAMIC ACID IN THE MANAGEMENT OF POSTPARTUM HEMORRHAGE
Authors :
Alaa Ahmed Elsayed
Abstract :
Introduction: The reduction of postpartum hemorrhage (PPH) fatalities through early tranexamic acid treatment has significant global implications for obstetrical care. Further research is necessary to determine the relative benefits and risks of tranexamic acid in the prevention of postpartum hemorrhage. The majority of postpartum hemorrhage deaths occur in low- and middle-income nations, where access to tranexamic acid treatment is frequently limited. Tranexamic acid, or TXA, has become a vital tool for managing blood loss during pregnancy in the last few decades. Currently, prophylaxis is being researched in high-risk groups, including women who have placenta previa or prepartum anemia. TXA effectively lowers morbidity and mortality associated with postpartum hemorrhage (PHH) during active PPH due to blood loss.
Aim of the study: The aim of the present study is to understand the role of tranexamic acid in the management of postpartum hemorrhage
Methodology: The study is a comprehensive research of PUBMED since the year 1983 to 2019.
Conclusion: Tranexamic acid is a molecular analog of lysine that prevents bleeding by decreasing the binding of plasminogen and tPA to fibrin, which inhibits fibrinolysis, the enzymatic breakdown of fibrin blood clots. Postpartum hemorrhage can be safely and effectively treated with tranexamic acid. Tranexamic acid reduces bleeding-related deaths by one-third when administered early. Since tranexamic acid is most effective when administered within three hours of childbirth and shows no discernible benefit after that, prompt treatment is essential for women suffering from post-partum hemorrhage, who often bleed to death.
Keywords: postpartum hemorrhage, Tranexamic acid, maternal health
Cite This Article:
Please cite this article in press Alaa Ahmed Elsayed., The Role Of Tranexamic Acid In The Management Of Postpartum Hemorrhage. .,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Gelebo K G, Mulugeta H, Mossie A, Geremu K, & Darma B (2024). Tranexamic acid for the prevention and treatment of postpartum hemorrhage in resource-limited settings: a literature review. Annals of Medicine and Surgery, 86(1), 353-360.
2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller A B, Daniels J, & Alkema, L (2014). Global causes of maternal death: a WHO systematic analysis. The Lancet global health, 2(6), e323-e333.
3. Carroli G, Cuesta C, Abalos E, & Gulmezoglu A M (2008). Epidemiology of postpartum haemorrhage: a systematic review. Best practice & research Clinical obstetrics & gynaecology, 22(6), 999-1012.
4. Hellgren M (2003). Hemostasis during normal pregnancy and puerperium. In Seminars in thrombosis and hemostasis (Vol. 29, No. 02, pp. 125-130). Copyright© 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662.
5. Kruithof E K, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, & Bachmann F (1987). Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.
6. James A H (2009). Venous thromboembolism in pregnancy. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(3), 326-331.
7. Lucas M A, Fretto L J, & McKee P A (1983). The binding of human plasminogen to fibrin and fibrinogen. Journal of Biological Chemistry, 258(7), 4249-4256.
8. Cesarman‐Maus G, & Hajjar K A (2005). Molecular mechanisms of fibrinolysis. British journal of haematology, 129(3), 307-321.
9. Brenner A, Ker K, Shakur-Still H, & Roberts I (2019). Tranexamic acid for post-partum haemorrhage: What, who and when. Best Practice & Research Clinical Obstetrics & Gynaecology, 61, 66-74.
10. World Health Organization. (2012). WHO recommendations for the prevention and treatment of postpartum haemorrhage. World Health Organization.
11. Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, & Akintan A (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. Published online, April 26, 2017.
12. Shakur H, Beaumont D, Pavord S, Gayet‐Ageron A, Ker K, Mousa H A, & Cochrane Pregnancy and Childbirth Group. (1996). Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database of Systematic Reviews, 2018(2).
13. Gayet-Ageron, A, Prieto-Merino D, Ker K, Shakur H, Ageron F X, Roberts I, & Pepple T (2018). Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. The Lancet, 391(10116), 125-132.
14. WHO Guidelines Approved by the Guidelines Review Committee. (2012). WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization.
15. World Health Organization (2017). Updated WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage: highlights and key messages from the World Health Organization’s 2017 global recommendation (No. WHO/RHR/17.21). World Health Organization.